Litracen
Litracen (N-7,049) is a tricyclic antidepressant which was never marketed.[1][2]
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H23N |
| Molar mass | 277.411 g·mol−1 |
| 3D model (JSmol) | |
| |
See also
References
- David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
- Nielsen IM, Nymark M, Hougs W, Pedersen V (February 1966). "The pharmacological properties of melitracen (N 7001) and litracen (N 7049)". Arzneimittel-Forschung. 16 (2): 135–40. PMID 6014004.
| 5-HT1AR agonists | |
|---|---|
| GABAAR PAMs |
|
| Gabapentinoids (α2δ VDCC blockers) | |
| Antidepressants |
|
| Sympatholytics (Antiadrenergics) |
|
| Others | |
| |
| α1 |
| ||||
|---|---|---|---|---|---|
| α2 |
| ||||
| β |
| ||||
| See also | |||||
| |||||||||||||||||||||||||
| H1 |
|
|---|---|
| H2 |
|
| H3 |
|
| H4 |
|
See also: Receptor/signaling modulators • Monoamine metabolism modulators • Monoamine reuptake inhibitors | |
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
| Classes | |
|---|---|
| Antidepressants (TCAs and TeCAs) |
|
| Antihistamines |
|
| Antipsychotics |
|
| Anticonvulsants | |
| Others |
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.